Cancer, the uncontrolled growth and spread of malignant cells that can affect almost any tissue of the body, continues to be a major burden to public health. Anticancer chemotherapy is the most important adjuvant therapy, but the targeted and effective therapy to the tumorous tissues or organs, however, remains as a significant challenge in chemotherapy. The proposed work will develop molecular nanofibers of small molecules for controlling the behavior and the fate of cells. The goal of this work is to explore cellular responses to enzyme-instructed formation of molecular nanofibers and eventually develop new nanomedicines to target cancer cells. This application is both hypothesis and design driven. We hypothesize that enzyme- instructed molecular self-assembly, as a unique way to create molecular nanofibers, can modulate extra- and intracellular microenvironment and selectively lead to death of cancer cells. To validate the hypothesis, we will design molecules that self-assemble to form nanofibers upon the action of extra- or intracellular enzyme(s), characterize the physiochemical properties of the nanofibers, and assess the biological properties and effects of the formation of molecular nanofibers in vitro and in vivo. Specifically, this proposed research will (i) design and synthesize substrates that can be converted into molecular nanofibers by enzyme catalysis;(ii) characterize the enzyme-catalyzed reactions of the designed precursors and the behavior and properties of the corresponding molecular nanofibers;(iii) evaluate the activity of the molecular nanofibers against representative cancer cell lines in vitro;and (iv) examine formation and anticancer effects of the molecular nanofibers in vivo using animal models. This research will potentially provide a new platform for creating synthetic nanostructures as nanomedicine to target cancer cells. We anticipate that this new approach will improve fundamental understanding of cancer therapy, provide guiding principles to design anticancer agents at nanoscale, and ultimately lead to a new paradigm of cancer therapy that are based on the integration of molecular self-assembly and enzyme catalysis.
The overall goal of this work is to develop a novel approach for creating nanomedicine to target cancer cells. Using enzyme to instruct the formation of synthetic nanostructures, this approach will ultimately lead to a new paradigm of cancer therapy for improving health and quality of life for the millions of people who will need anticancer treatment in the future.
|Wu, Dongdong; Du, Xuewen; Shi, Junfeng et al. (2015) The first CD73-instructed supramolecular hydrogel. J Colloid Interface Sci 447:269-72|
|Shi, Junfeng; Du, Xuewen; Huang, Yibing et al. (2015) Ligand-receptor interaction catalyzes the aggregation of small molecules to induce cell necroptosis. J Am Chem Soc 137:26-9|
|Zhou, Rong; Xu, Bing (2014) Insight of the cytotoxicity of the aggregates of peptides or aberrant proteins: a meta-analysis. PLoS One 9:e95759|
|Du, Xuewen; Zhou, Jie; Xu, Bing (2014) Supramolecular hydrogels made of basic biological building blocks. Chem Asian J 9:1446-72|
|Yuan, Dan; Zhou, Rong; Shi, Junfeng et al. (2014) Enzyme-instructed self-assembly of hydrogelators consisting of nucleobases, amino acids, and saccharide. RSC Adv 4:26487-26490|
|Kuang, Yi; Gao, Yuan; Shi, Junfeng et al. (2014) The first supramolecular peptidic hydrogelator containing taurine. Chem Commun (Camb) 50:2772-4|
|Kuang, Yi; Du, Xuewen; Zhou, Jie et al. (2014) Supramolecular nanofibrils inhibit cancer progression in vitro and in vivo. Adv Healthc Mater 3:1217-21|
|Wu, Dongdong; Zhou, Jie; Shi, Junfeng et al. (2014) A naphthalene-containing amino acid enables hydrogelation of a conjugate of nucleobase-saccharide-amino acids. Chem Commun (Camb) 50:1992-4|
|Shi, Junfeng; Du, Xuewen; Yuan, Dan et al. (2014) D-amino acids modulate the cellular response of enzymatic-instructed supramolecular nanofibers of small peptides. Biomacromolecules 15:3559-68|
|Kuang, Yi; Long, Marcus J C; Zhou, Jie et al. (2014) Prion-like nanofibrils of small molecules (PriSM) selectively inhibit cancer cells by impeding cytoskeleton dynamics. J Biol Chem 289:29208-18|
Showing the most recent 10 out of 32 publications